Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Study Comparing 0.9 g and 1.25 g EstroGel® 0.03% Doses With Placebo in the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated With Menopause

NCT00160173 is registered in ClinicalTrials.gov with ASCEND Therapeutics as lead sponsor.

NCT NCT00160173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00160173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Study Comparing 0.9 g and 1.25 g EstroGel® 0.03% Doses With Placebo in the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated With Menopause
Lead sponsor
ASCEND Therapeutics
Phase
Phase 4
Overall status
Completed
Start date
December 2, 2004
Completion date
September 6, 2005
Enrollment
221 (actual)
Sites
109

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal symptoms